Press Releases
Date Title and Summary View
Nov 19, 2016 Significant reduction of proteinuria compared to irbesartan Statistically significant difference in modified partial remission; complete remission also observed Further analysis supports sparsentan generally safe and well-tolerated SAN DIEGO, Nov. 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced additional resul...
Nov 10, 2016 SAN DIEGO , Nov. 10, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a Phase 3 clinical trial evaluating RE-024, the Company's novel investigational replacement therapy, for the treatment of p...
Nov 3, 2016 Positive top-line results from DUET announced in September; additional data to be presented at ASN Kidney Week 2016 Third quarter revenues increased 21 percent year-over-year SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its third quarter 2016 financial results. Net product sales for the third qu...
Oct 21, 2016 SAN DIEGO, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that additional data from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS) will be presented at the late-breaking High-Impact Clinical Trials oral session at the American Society of Nephrology (ASN) Kidney ...
Oct 20, 2016 SAN DIEGO, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report third quarter 2016 financial results on Thursday, November 3, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:...
Oct 6, 2016 SAN DIEGO, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced Alvin Shih, M.D., will be stepping down from his position as executive vice president and head of research and development to become chief executive officer of a start-up biotechnology company. Dr. Shih will remain in his current role until October 31, 2016...
Sep 30, 2016 SAN DIEGO, Sept. 30, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that its Board of Directors has granted an inducement award pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules to Julio Gagne in connection with his employment as vice president, Program Management. Mr. Gagne's employment with Retrophin began tod...
Sep 14, 2016 SAN DIEGO, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih, M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday, September 28, 2016 at 11:05 a.m. ET. A live webcas...
Sep 7, 2016 Combined sparsentan treatment group experienced 44.8 percent reduction of proteinuria, more than double the reduction of irbesartan; achieves statistical significance in primary efficacy endpoint Preliminary safety findings show sparsentan was generally safe and well-tolerated Conference call scheduled for today at 8:30 a.m. ET SAN DIEGO, S...
Aug 15, 2016 SAN DIEGO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Neil McFarlane has been appointed chief operating officer. In this newly created position, Mr. McFarlane will help guide the Company's daily operations with principal responsibility for commercial operations, business development, patient services, and prog...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase